<p>分析师们可能对 <strong>Blue Jet Healthcare Limited</strong> (NSE:BLUEJET) 的预期过于乐观，因为该公司在上周发布季度业绩时未能达到预期。不幸的是，Blue Jet Healthcare 的盈利严重失利。收入为 ₹19 亿，低于预期的 18%，法定每股收益为 ₹2.32，低于预期 35%。在业绩公布后，分析师们更新了他们的盈利模型，了解他们是否认为公司的前景发生了重大变化，或者一切如常，将是很有意义的。因此，我们收集了最新的业绩后法定共识预期，以了解明年可能会发生什么。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前投资。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1676807750-earnings-and-revenue-growth-1-dark-2/1771378630409?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1676807750-earnings-and-revenue-growth-1-dark-2/1771378630409"/></p>
<p>NSEI:BLUEJET 收益和收入增长 2026 年 2 月 18 日</p>
<p>考虑到最新的业绩，Blue Jet Healthcare 八位分析师的共识预测是 2027 年收入为 ₹131 亿。这反映出与过去 12 个月相比，收入有显著的 25% 增长。法定每股收益预计将上升 6.9%，达到 ₹18.09。在这份盈利报告之前，分析师们曾预测 2027 年收入为 ₹148 亿，每股收益 (EPS) 为 ₹22.52。看起来在这些结果公布后，市场情绪大幅下降，收入预期被大幅下调，每股收益数字也大幅下降。</p>
<p>查看我们对 Blue Jet Healthcare 的最新分析</p>
<p>共识目标价下降了 30%，降至 ₹499，疲软的盈利前景显然导致了估值预期的下降。然而，这并不是我们可以从这些数据中得出的唯一结论，因为一些投资者在评估分析师目标价时也喜欢考虑预期的差异。目前，最乐观的分析师将 Blue Jet Healthcare 的每股价值定为 ₹835，而最悲观的则定为 ₹330。在这种情况下，我们可能会对分析师的预测赋予较少的价值，因为如此广泛的预期范围可能意味着该业务的未来难以准确估值。考虑到这一点，我们不会过于依赖共识目标价，因为这只是一个平均值，分析师们显然对该业务有着截然不同的看法。</p>
<p>当然，另一种看待这些预测的方法是将其与行业本身进行对比。从最新的预估来看，Blue Jet Healthcare 的增长率预计将显著加快，预计到 2027 年的年化收入增长率为 19%，明显快于过去五年 16% 的历史增长率。与同一行业的其他公司相比，后者预计年收入增长 10%。考虑到收入的加速增长，显然 Blue Jet Healthcare 的增长速度预计将远快于其行业。</p>
<h2>结论</h2>
<p>最大的问题是分析师们下调了每股收益预期，这表明 Blue Jet Healthcare 可能面临业务阻力。不幸的是，他们也下调了收入预期，但最新的预测仍然暗示该业务将比更广泛的行业增长得更快。此外，分析师们还下调了他们的目标价，表明最新消息导致了对该业务内在价值的更大悲观情绪。</p>
<p>话虽如此，公司的盈利长期轨迹远比明年的情况更为重要。我们对 Blue Jet Healthcare 的预测一直延续到 2028 年，您可以在我们的平台上免费查看。</p>
<p>您还可以查看我们对 Blue Jet Healthcare 董事会和首席执行官薪酬及经验的分析，以及公司内部人士是否在购买股票。</p>
<h3>估值复杂，但我们在这里为您简化。</h3>
<p>通过我们的详细分析，发现 Blue Jet Healthcare 是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易及其财务状况。</strong></p>
<p>访问免费分析</p>

<p>蓝天医疗有限公司（NSE:BLUEJET）公布了令人失望的季度业绩，收入为 19 亿印度卢比，比预期低 18%，每股收益为 2.32 印度卢比，低于预期 35%。在此次业绩失利后，分析师们已修订了他们的预测，预计 2027 年的收入将达到 131 亿印度卢比，增长 25%，但每股收益预计仅增长 6.9%，达到 18.09 印度卢比。共识目标价已下调 30%，至 499 印度卢比，反映出市场情绪的下降。尽管评级下调，蓝天医疗预计将以高于行业平均水平的速度增长，预计到 2027 年年均收入增长 19%</p>

<p>The analysts might have been a bit too bullish on <strong>Blue Jet Healthcare Limited</strong> (NSE:BLUEJET), given that the company fell short of expectations when it released its quarterly results last week. Unfortunately, Blue Jet Healthcare delivered a serious earnings miss. Revenues of ₹1.9b were 18% below expectations, and statutory earnings per share of ₹2.32 missed estimates by 35%. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.</p>
<div class="lb-trans"><p>分析师们可能对 <strong>Blue Jet Healthcare Limited</strong> (NSE:BLUEJET) 的预期过于乐观，因为该公司在上周发布季度业绩时未能达到预期。不幸的是，Blue Jet Healthcare 的盈利严重失利。收入为 ₹19 亿，低于预期的 18%，法定每股收益为 ₹2.32，低于预期 35%。在业绩公布后，分析师们更新了他们的盈利模型，了解他们是否认为公司的前景发生了重大变化，或者一切如常，将是很有意义的。因此，我们收集了最新的业绩后法定共识预期，以了解明年可能会发生什么。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前投资。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1676807750-earnings-and-revenue-growth-1-dark-2/1771378630409" alt="" original-src="https://images.simplywall.st/asset/chart/1676807750-earnings-and-revenue-growth-1-dark-2/1771378630409"/></p>
<p>NSEI:BLUEJET Earnings and Revenue Growth February 18th 2026</p>
<div class="lb-trans"><p>NSEI:BLUEJET 收益和收入增长 2026 年 2 月 18 日</p>
</div><p>Taking into account the latest results, the consensus forecast from Blue Jet Healthcare's eight analysts is for revenues of ₹13.1b in 2027. This reflects a substantial 25% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to rise 6.9% to ₹18.09. Before this earnings report, the analysts had been forecasting revenues of ₹14.8b and earnings per share (EPS) of ₹22.52 in 2027. It looks like sentiment has declined substantially in the aftermath of these results, with a real cut to revenue estimates and a substantial drop in earnings per share numbers as well.</p>
<div class="lb-trans"><p>考虑到最新的业绩，Blue Jet Healthcare 八位分析师的共识预测是 2027 年收入为 ₹131 亿。这反映出与过去 12 个月相比，收入有显著的 25% 增长。法定每股收益预计将上升 6.9%，达到 ₹18.09。在这份盈利报告之前，分析师们曾预测 2027 年收入为 ₹148 亿，每股收益 (EPS) 为 ₹22.52。看起来在这些结果公布后，市场情绪大幅下降，收入预期被大幅下调，每股收益数字也大幅下降。</p>
</div><p>View our latest analysis for Blue Jet Healthcare</p>
<div class="lb-trans"><p>查看我们对 Blue Jet Healthcare 的最新分析</p>
</div><p>The consensus price target fell 30% to ₹499, with the weaker earnings outlook clearly leading valuation estimates. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Blue Jet Healthcare at ₹835 per share, while the most bearish prices it at ₹330. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.</p>
<div class="lb-trans"><p>共识目标价下降了 30%，降至 ₹499，疲软的盈利前景显然导致了估值预期的下降。然而，这并不是我们可以从这些数据中得出的唯一结论，因为一些投资者在评估分析师目标价时也喜欢考虑预期的差异。目前，最乐观的分析师将 Blue Jet Healthcare 的每股价值定为 ₹835，而最悲观的则定为 ₹330。在这种情况下，我们可能会对分析师的预测赋予较少的价值，因为如此广泛的预期范围可能意味着该业务的未来难以准确估值。考虑到这一点，我们不会过于依赖共识目标价，因为这只是一个平均值，分析师们显然对该业务有着截然不同的看法。</p>
</div><p>Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Blue Jet Healthcare's rate of growth is expected to accelerate meaningfully, with the forecast 19% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 16% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 10% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Blue Jet Healthcare is expected to grow much faster than its industry.</p>
<div class="lb-trans"><p>当然，另一种看待这些预测的方法是将其与行业本身进行对比。从最新的预估来看，Blue Jet Healthcare 的增长率预计将显著加快，预计到 2027 年的年化收入增长率为 19%，明显快于过去五年 16% 的历史增长率。与同一行业的其他公司相比，后者预计年收入增长 10%。考虑到收入的加速增长，显然 Blue Jet Healthcare 的增长速度预计将远快于其行业。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>结论</h2>
</div><p>The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Blue Jet Healthcare. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.</p>
<div class="lb-trans"><p>最大的问题是分析师们下调了每股收益预期，这表明 Blue Jet Healthcare 可能面临业务阻力。不幸的是，他们也下调了收入预期，但最新的预测仍然暗示该业务将比更广泛的行业增长得更快。此外，分析师们还下调了他们的目标价，表明最新消息导致了对该业务内在价值的更大悲观情绪。</p>
</div><p>With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Blue Jet Healthcare going out to 2028, and you can see them free on our platform here.</p>
<div class="lb-trans"><p>话虽如此，公司的盈利长期轨迹远比明年的情况更为重要。我们对 Blue Jet Healthcare 的预测一直延续到 2028 年，您可以在我们的平台上免费查看。</p>
</div><p>You can also see our analysis of Blue Jet Healthcare's Board and CEO remuneration and experience, and whether company insiders have been buying stock.</p>
<div class="lb-trans"><p>您还可以查看我们对 Blue Jet Healthcare 董事会和首席执行官薪酬及经验的分析，以及公司内部人士是否在购买股票。</p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值复杂，但我们在这里为您简化。</h3>
</div><p>Discover if Blue Jet Healthcare might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现 Blue Jet Healthcare 是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易及其财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>访问免费分析</p>
</div>

盈利未达预期：Blue Jet Healthcare Limited 的每股收益低于预期 35%，分析师正在调整他们的预测